Recursion Pharmaceuticals, Inc. RXRX Business Segments — Net loss
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Recursion Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:NetIncomeLoss.
The official record: Recursion Pharmaceuticals, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Recursion Pharmaceuticals, Inc.'s business segments — net loss.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Recursion Pharmaceuticals, Inc.'s business segments — net loss?
- Recursion Pharmaceuticals, Inc. (RXRX) reported business segments — net loss of -$117.5M in Q1 2026.
- How has Recursion Pharmaceuticals, Inc.'s business segments — net loss changed year-over-year?
- Recursion Pharmaceuticals, Inc.'s business segments — net loss increased by 42.0% year-over-year, from -$202.49M to -$117.5M.
- What is the long-term trend for Recursion Pharmaceuticals, Inc.'s business segments — net loss?
- Over 3 years (2022 to 2025), Recursion Pharmaceuticals, Inc.'s business segments — net loss has grown at a 39.1% compound annual growth rate (CAGR), from -$239.48M to -$644.76M.
- What does business segments — net loss mean?
- This metric measures the bottom-line financial performance of the business segment after accounting for all revenues and operating expenses. A negative value indicates that the segment's costs, including research, development, and administrative overhead, exceed the revenue generated. It is a critical indicator of the segment's current profitability status and the burn rate required to sustain its specific operational objectives.